Review Article

Acute Hemorrhagic Leukoencephalitis (AHLE): A Comprehensive Review on Causes, Symptoms, Link with COVID-19, Diagnosis, and Treatment

Mona Alromaihi

Department of Pediatrics, College of Medicine, Qassim University, Buraydah 51452, Saudi Arabia

Correspondence should be addressed to Mona Alromaihi; 26607@qu.edu.sa

Received 20 May 2022; Revised 12 October 2022; Accepted 1 November 2022; Published 15 November 2022

Academic Editor: Silvia Lacchini

Copyright © 2022 Mona Alromaihi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute hemorrhagic leukoencephalitis (AHLE), also called Hurst disease, is a rare demyelinating disease of the central nervous system (CNS) marked by rapid progression and acute inflammation of the white matter. Due to the correlation in their suspected postinfectious autoimmune pathogenesis, it is regarded as the most severe form of acute disseminated encephalomyelitis (ADEM). Because this clinical scenario has a high mortality rate, aggressive and immediate treatment is required. Although the exact cause of AHLE is unknown, it usually occurs after a bacterial or viral infection, or, less frequently, after a measles or rabies vaccination. AHLE has been reported in patients with coronavirus disease 2019 (COVID-19) as a rare but serious neurological complication. However, due to the lack of evidence-based diagnostic criteria, diagnosis is difficult. The small number of cases described in the literature, which most likely reflects underreporting and/or low incidence, necessitates greater public awareness. Increased clinical suspicion and early imaging identification of this entity may allow clinicians to pursue more aggressive treatment options, potentially reducing fatal outcomes. This study focuses on symptoms and causes of AHLE, difference between AHLE and ADME, diagnosis and treatment of AHLE, and its link with COVID-19.

1. Introduction

Acute hemorrhagic leukoencephalitis (AHLE) is a rare demyelination disorder that causes rapid neurologic deterioration and death. Although its precise pathophysiology is unknown, it is most commonly described as a postinfectious complication of an upper respiratory illness [1, 2]. AHLE is a severe form of ADEM. AHLE has a higher rate of morbidity and mortality than ADEM, but it is much less common. AHLE is likely to be underreported and underrecognized due to the disease’s rarity and a lengthy diagnostic procedure [3, 4].

AHLE is also known as Weston-Hurst syndrome or Hurst disease. Weston-Hurst was the one to describe this syndrome in 1941, when he reported two adults who developed acute encephalopathy with focal neurologic signs following a respiratory infection. The first patient (housewife) died two days after developing aphasia, headache, and right-sided hemiparesis, and the second patient (municipal worker) died one week after developing aphasia, confusion, seizures, and going into a coma. The pathologic lesions seen in the two patients were similar, with edema; hemorrhagic white matter lesions, primarily limited to one cerebral hemisphere; demyelination; perivascular polymorphonuclear infiltrates; necrosis; and fibrin deposition in and around blood vessels [5, 6].

AHLE is a type of brain inflammatory disease that primarily affects the cerebrum, but can also affect the brain stem, cerebellum, and spinal cord. The condition is thought to be a hyperacute autoimmune reaction triggered by a cross-reaction between the patient’s own CNS tissues and antigens from an infectious agent. It is a rare CNS acute inflammatory myelinopathy that causes progressive loss of consciousness leading to focal neurological dysfunction and coma. AHLE is distinguished by an acute onset and rapid progression of inflammation, with symmetrical, multifocal brain lesions associated with acute edematous necrosis and hemorrhage [7]. This rare disease primarily affects
young adults and is frequently linked to previous (1–4 weeks) respiratory tract infections. The overall mortality rate of AHLE is high, and survivors often have neurological deficits. Death is common in the first week of the disease, with an estimated 70% mortality rate [8].

2. Epidemiology

The majority of the initial reports came from the Australia and United Kingdom. The following descriptions came from the Belgium, United States, France, Eastern Europe, Germany, Japan, and Turkey. Men are affected twice as likely as women [9].

3. Pathology, Experimental Models, and Pathogenesis

The presence of inflammation with tissue damage or perivascular demyelination is a characteristic feature of AHLE, similar to ADEM. The degree of lymphocytic infiltration, on the other hand, is less pronounced overall. There are numerous granulocytes present, as well as small perivascular hemorrhages and fibrinoid necrosis on the walls of some veins, in contrast to ADEM [10].

AHLE was initially thought to be a subtype of ADEM with a more severe disease course and aggressive lesions. This viewpoint is supported by the observation in experimental animals that autoimmune encephalomyelitis can progress to a very severe aggressive variant known as hyperacute autoimmune encephalitis [11]. Its pathology is similar to that of AHLE. Methods for inducing hyperacute experimental autoimmune encephalomyelitis (EAE) in animals include the changes in the immunization protocol (e.g., immune-stimulating adjuvant selection), use of specific animal strains (genetic background), or immune system manipulation prior to immunization. However, the pathogenic backgrounds of ADEM and AHLE in humans may differ. The most common association of AHLE with influenza virus infections is distinct from the range of infectious diseases associated with ADEM [12]. Recent genetic studies have revealed that genetic changes in the target tissue or immune system may influence the infection-triggered inflammatory response in AHLE. Genetic polymorphisms in a gene coding for the complement factor 1 were discovered in a family with two children affected by AHLE [12]. Complement is involved in immune-mediated tissue injury and inflammation, and its stimulation has been linked to hyperacute EAE lesions, so this link could explain why these patients have such severe inflammatory CNS disease. A number of other studies have found a link between common viral infections (primarily parainfluenza and influenza), ANE, and mutations in the RAN-binding protein 2 gene (RANBP2) [13]. RANBP2 is a nuclear pore protein whose dysfunction causes energy deficit in tissues infected by acute infections. The exact mechanism by which these mutations affect inflammatory mechanisms is unknown, these findings suggest that AHLE may be caused by infection-triggered (potentially autoimmune) inflammatory response that is enhanced by the dysfunction of genes responsible for the regulation of immune-mediated tissue damage [14].

4. Causes and Clinical Manifestations

The onset of AHLE is sudden and, in some cases, violent. It manifests between 2 days and 2 weeks after a 3 to 5-day prodrome [20]. It is most common in the winter and autumn. The most common antecedent (32–35%) is viral respiratory infections, but there is mostly no prodrome (18%) [5]. In one-third of cases, the upper respiratory infection is followed by a period of symptom-free time before neurologic symptoms appear. Patients in hematologic remission from acute myeloid leukemia may be especially vulnerable to this rare condition (2%) [15]. Two-thirds are men. The most common ages are 20 to 40 years, but children and the adults have also been affected. Twelve percent have preexisting auto immune diseases [5].

The course is usually short and ends with disability or death. Headache, fever up to 106°F, photophobia, meningeal irritation, neck stiffness, confusion, and lethargy last several days and are followed by a coma that deepens over 4 to 10 days. It is possible to do a biphasic course over several weeks. High-dose steroids were withdrawn before the second episode in one case of biphasic disease, possibly leading to recrudescence [16]. The diffuse and massive necrosis of CNS white matter causes a wide range of neurologic symptoms. Visual field disturbances, gaze preferences, pseudobulbar palsy, aphasia, or mutism may appear to be caused by a cortical disturbance, but they are actually caused by white matter lesions undercutting cortical connections. Early signs of incontinence and motor and sensory disturbances appear [17]. Toes are usually upgoing, and reflexes are usually hyperactive. 50% of the patients have hemiparesis. Seizures or status epileptics, involuntary movements, and dysarthria affect a smaller proportion of the population. One-third of people have papilledema, a symptom of high intracranial pressure. Death occurs as a result of herniation and brain swelling. Cerebrospinal fluid (CSF) pleocytosis resolves after a few weeks, and clinical symptoms improve over a few weeks to months [18].

Clinically, most patients with AHLE suffer from acute encephalopathy, which rapidly worsens within a few days. Almost half of those affected die as the disease progresses, and those who survive have serious neurological consequences. In most cases, laboratory tests show elevated levels of inflammatory markers such as C-reactive protein (CRP), D-dimer, procalcitonin, and serum ferritin [5, 19].

Fever, headache, fatigue, nausea, neck stiffness, vomiting, seizures, or coma are common symptoms in patients diagnosed with AHLE (Figure 1). There is also evidence of brain hemorrhage resulting in white matter damage. Symptoms usually appear 2 to 12 days after a nonspecific upper respiratory infection or vaccination [20]. In addition to these symptoms, patients with AHLE may have other comorbid medical conditions such as:

(i) Respiratory infection
(ii) Abdominal pain
(iii) Focal neurologic signs
(iv) Encephalopathy
(v) Photophobia
(vi) Gaze deviation
(vii) Motor weakness
(viii) Altered state of consciousness
(ix) Sensory changes
(x) Aphasia in older patients

The disease is aggressive and severe, with patients progressing from early localized neurological symptoms to seizures and coma within days [21, 22]. Fever is usually associated with acute neurological disease. Untreated patients have a very high mortality rate. A clinical evaluation one month after onset helps determine the prognosis for long-term outcomes in surviving patients. MRI changes are similar as seen in ADEM, but with more severe brain edema and, unlike ADEM, petechial hemorrhages are present. Increased protein levels and leukocyte counts in the cerebrospinal fluid (CSF) indicate inflammation, but no oligoclonal bands or intrathecal immunoglobulin synthesis are found [10].

Although the underlying cause of AHLE is uncertain, researchers have discovered a correlation between the onset of symptoms and bacterial or viral inflammation (Figure 1). Hence, it is thought that AHLE is the result of an autoimmune response to a bacteria or virus [23]. Numerous viruses and bacteria have been linked to ADEM/AHLE (Table 1).

5. Pathophysiology

Demyelination occurs when human myelin antigens react with bacterial or viral antigens, resulting in the collapse of the nerve fibers’ protective unit. Because autoimmune processes usually target the CNS rather than the peripheral nervous system, this immune response is unusual. Both areas of the nervous system are targeted in the case of AHLE [25]. The autoimmune process is thought to be initiated by molecular mimicry between antigens of the bacterial or viral pathogen and myelin antigens. Myelin basic protein peptides have been found to have homologies with viruses such as influenza, measles, adenovirus, hepatitis B virus, and Epstein-Barr virus. Sensitivity to this type of autoimmunity is predominant, as some molecules of the major class I and II histocompatibility complex are more effective in presenting homologous peptides for T cell activation than others may be affected by haplotypes of compatible gene complexes. The disease’s rarity is probably due to predisposing genetic factors. Studies linking post vaccination encephalomyelitis caused by the Semple rabies vaccine to human leukocyte antigen-DR17 and -DR9, as well as human leukocyte antigen-DRB1*01 and -DRB1*03(017) with ADEM in the Russian population, implying a genetic link [26].

In a recent study, researchers found support for this hypothesis by injecting a Theiler’s murine encephalomyelitis virus into mice. In the experiment, CD8+ T cells were activated in C57BL/6 mice, resulting in hemorrhagic demyelination in 24 hours. This was the first time an AHLE murine model had been shown [27].

Meanwhile, several studies have found a tenuous link between the disorder and measles, rabies, or vaccination; however, further research is required to confirm this link [20, 23].

6. AHLE and ADEM

AHLE and ADEM share many features. This is because both are usually preceded by upper respiratory tract infections, or EBV, HSV, mumps, mumps, influenza, rubella virus infections, or vaccination. Despite the fact that many infectious diseases and vaccine precursors are associated with both diseases, active research into these causes is often futile. AHLE is more commonly diagnosed in young adults than ADEM, which is more commonly diagnosed in children. AHLE may be more common in people of Pacific Island ancestry and/or Asian, but ADEM does not affect people of any ethnicity specifically [25, 28].

It is unclear whether ADEM and AHLE are part of a series of diseases with the same underlying process resulting from an autoimmune response caused by prodromal infection, or if they are separate entities. However, different types of CNS infiltrates, such as neutrophils in AHLE and lymphocytes in ADEM, do not support the idea of spectrum diseases. Many autoimmune response mechanisms and
histopathologic features are similar in AHLE and ADEM. Hence, AHLE is regarded as the most severe subtype of ADEM [28].

Because ADEM and AHLE are on the same disease spectrum, there is no clear distinction between the two. Hence, distinguishing the two with MRI is difficult. White matter lesions in both diseases can be caused by edema and inflammation at first, and then by axonal loss and demyelination later on [29]. ADEM has less cerebral edema, smaller lesions, and rare hemorrhage. Further distinction is that in AHLE, the subcortical U fibers are usually spared. AHLE produces a predominantly neutrophilic infiltrate with pericapillary ball and ring hemorrhages and hematomas, whereas ADEM produces a predominantly lymphocyte-rich infiltrate [30]. Table 2 compares AHLE and ADEM in terms of neuroradiologic, clinical, and laboratory differences.

### 7. Diagnosis

AHLE is diagnosed primarily through neuroimaging, CSF analysis, and histopathology. Due to the lack of formal research, guidelines for defining diagnostic algorithms are absent and cannot be derived from current data. Furthermore, most clinical scenarios described in the literature include signs and symptoms that lead clinicians to suspect ADEM. Individual clinical features do not make a definitive distinction between ADEM and AHLE, but the coexistence of multiple signs and symptoms helps to distinguish between these two entities. Given that the clinical course and syndromic appearance of ADEM and AHLE are frequently indistinguishable, treatment options are similar, and the body of evidence for the latter is limited for both entities, the need for a reliable differentiation appears dubious [5].

Clinical examination and, more importantly, CT scans, CSF studies, brain biopsy, and MRIs can be used to make a diagnosis [23, 31]. CSF tests for increased protein levels and leukocytosis are usually positive, but polymerase chain reaction testing and infectious cause cultures are usually negative. A head CT scan may reveal hypodensities in the affected grey and white matter. Hyperintense T2-weighted lesions will be visible on a brain MRI. Better visualization will be provided by the FLAIR sequence [31]. A brain biopsy may reveal pathognomonic findings such as demyelination, hemorrhagic necrosis, and perivascular infiltrates. Although direct brain tissue examination is the most accurate method of diagnosing AHLE, this might not be possible in all patients [23]. Clinical diagnosis can be made based on the severity of the symptoms, the disease’s clinical course, and radiological findings. The radiological findings of ADEM and AHLE are similar [23] [24].

AHLE is histopathologically characterized by necrosis and perivascular microhemorrhages, demyelination with fibrin exudate, and axonal injury. Perivascular inflammation is of variable severity, but is usually neutrophilic with lymphocyte and macrophage infiltration [32, 33]. Many people die as a result of edema and massive hemorrhage caused by herniation. Finally, immunosuppression and cerebral edema management are the treatment goals [34].

MRI is useful in the early detection of AHLE, which is characterized by white matter tracts with hemorrhage on SWI and sparing of grey matter. The changes are usually multiple, with the parietal and frontal lobes most affected, but the brainstem, spinal cord, and basal ganglia can also be affected [30, 35, 36]. Brain MRI is critical because it detects confluent white matter lesions with space-occupying effects, significant edema, and petechial hemorrhages. The lesions’ location appears to be highly variable. Nearly two-thirds of patients have uni- or bilateral hemispheric involvement, but other distributional patterns have been described. The presence of intraparenchymal hemorrhages on cerebral MRI, however, is the most useful feature in distinguishing AHLE from ADEM [26, 37].

### 8. Management and Treatment

The onset of AHLE symptoms occurs concurrently as the disease progresses, making it an extremely difficult condition to treat. Despite this, many current studies and clinical trials are focused on developing effective and long-term treatments for the disease [23].

No controlled studies or large case series have been published to help guide the management of this often fatal and rare condition. Management is based on expert opinion, knowledge of the underlying pathology, and isolated case reports data. Several case reports have been published reporting positive results from a variety of immunosuppressive methods, including intravenous immunoglobulins, high-dose corticosteroids, cyclophosphamide, and plasmapheresis [30]. Seales and Greer described how they used mannitol, hyperventilation, and phenobarbital to treat a patient with...
high intracranial pressure. The patient in that case had no long-term neurological effects. It has also been discussed how to treat raised intracranial pressure surgically [18, 33].

Treatment for AHLE has the potential to alter the disease's prognosis. The first line of treatment is aggressive ICP control, which may necessitate decompressive craniectomy in some cases. The majority of patients, however, can be treated medically [8]. Immunomodulation therapy is used in the second stage of treatment to deal with the persistently high levels of inflammation. Although no treatment guidelines for AHLE have been established, multiple studies and case reports suggest that IVIG, high-dose steroids, and plasmapheresis should be used as the primary treatment [23, 31, 33]. On initial presentation, a pulse dose of IV methylprednisolone, along with acyclovir and antibiotics, should be started. It should be taken for 3-5 days, then followed by 4-6 weeks of oral prednisolone [38]. Several case reports and small studies have demonstrated the

| Characteristics | AHLE | ADEM |
|-----------------|------|------|
| Age group affected | Young adults | Children |
| Epidemiology | Incidence unknown, Male predominance | Incidence 0.3–0.6 per 100,000 per year (i) Male predominance (ii) More common in children and teenagers |
| Triggering event | Respiratory tract infections | Respiratory tract infections, viral exanthema, and vaccination |
| Clinical findings | Focal neurological symptoms according to the location of lesions (i) Symptoms and signs of elevated intracranial pressure possible | Focal neurological symptoms according to the location of lesions (i) Unspecific encephalopathy |
| Clinical course | Fulminant, frequently evolving to coma/death within days | Less fulminant, coma unusual |
| Onset | Hyperacute, fulminant | Acute |
| Blood picture | Leukocytosis | Normal |
| Radiological findings | Larger lesions, confluent (i) Significant edema with space-occupying effect (Petechial) hemorrhages | Hyperintense lesions of the white matter No data |
| FLAIR SWI/T2* | Granulocytic pleocytosis (i) Elevated protein in 87% (ii) Normal glucose (iii) Possibly erythrocytes/ferritin | Protein increased in 23–62% of pediatric Patients Lymphocytic pleocytosis |
| Histological and laboratory findings CSF | Neutrophil-predominant leukocytosis Necrosis of small vessels (i) Perivascular fibrin exudation (ii) Hemorrhages ("ring-and-ball") (iii) Infiltration with neutrophils and macrophages (iv) Demyelination in later stages | No leukocytosis Perivascular demyelination with lymphocytic Infiltration |
| Peripheral blood histopathology | Demyelination, ring hemorrhages, and fibrinoid necrosis | Demyelination, Perivenular inflammation |
| Pathology | Elevated | Normal |
| ESR/acute phase reactants | CSF cellularity | Red blood cells, neutrophils Mononuclear |
| Urine | Occasionally proteinuria | Normal |
| Neuroimaging | Large lesions, hemorrhage, necrosis, and mass effect | Multifocal white matter lesions |
| Treatment options | (i) Glucocorticoids (ii) Plasmapheresis (iii) IVIG (iv) Rituximab, cyclophosphamide | (i) IVIG (ii) Glucocorticoids (iii) Plasmapheresis |
| Outcome | Poor | Generally good |

Table 2: Neuroradiologic, clinical, and laboratory differences between AHLE and ADEM [5].
efficacy of daily IVIG therapy, either as a single dose or as a five-day course. Despite the fact that no clinical trials comparing plasmapheresis and IVIG for the treatment of AHLE have been conducted, evidence from multiple series and case reports suggests that plasmapheresis should be used when steroid and IVIG fail [39].

Previous studies have reported monophasic disease with a good prognosis when the first attack is overcome [30]. There have been no reports of AHLE recurrence. It is also unclear whether the presence or absence of previous respiratory disease has prognostic value. AHLE is not only a diagnostic but also a therapeutic challenge, as treatment guidelines for AHLE are not well-established. Further research is needed to better characterize this rare disease and provide more information about treatment and prognosis options.

9. AHLE and COVID-19

COVID-19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been linked to neurological problems in a number of studies. [40, 41]. Most associated neurologic dysfunctions are mild symptoms such as dyspepsia and anosmia, but severe debilitating neuropathies such as meningoencephalitis and stroke are rare [42]. These symptoms are most likely caused by SARS-CoV-2 infecting the brain directly through olfactory neuroepithelium infection, or by circulating monocytes and lymphocytes that can cross the blood-brain barrier [43, 44]. Endothelial cells, neurons, glia, smooth muscle, and vascular pericytes all express the angiotensin-converting enzyme 2 (ACE2) receptor in the brain and spinal cord, which is the primary receptor for SARS-CoV-2 spike protein [45–47]. RT-PCR, immunohistochemistry (IHC), electron microscopy, and in situ hybridization (ISH) were all used for the detection of SARS-CoV-2 in the olfactory epithelium, brain, and cranial nerves [48–50]. Neuropathological findings such as microglial nodules, parenchymal lymphocytic and leptomeningeal inflammation, and neuronophagia are also consistent with a viral meningoencephalitis diagnosis. On hematoxylin and eosin- (H&E-) stained slides, however, neither viral inclusions nor cytopathic changes could be seen. Furthermore, in the several studies that have reported evidence of protein or viral RNA in the brainstem or cranial nerves, the distribution and degree of neuropathologic changes have shown no correlation with the amount of virus in a given area of pathology, implying that pathology is inferior to the systemic effects of viral infection. Evidently, convincing evidence has been found that systemic hypercoagulability is important in the COVID-19-related stroke process, as SARS-CoV-2 could elicit endotheliopathy and cytokine storm, resulting in histologic findings of microthrombi, hemorrhages, and infarcts [2, 51–53].

However, whether parainfectious, autoimmune-mediated processes such as ADEM or its hyperacute form AHLE can sincerely be attributed to COVID-19 remains debatable. One source of contention is the scarcity of neuropathological descriptions of ADEM and AHLE, despite the fact that a few clinical and imaging case studies of COVID-19 patients have revealed lesions characterization of ADEM or AHLE [54–57]. Only a few case reports with ADEM and AHLE neuropathological features in adult deaths from COVID-19 complications have been published so far. Another source of debate is whether the ADEM-like or AHLE-like pathology observed is the result of a basic demyelinating process, a secondary white matter lesion caused by coexisting vascular disease, or a combination of the two [58–60].

Despite the fact that patients with COVID-19 often have neurological symptoms, only a few cases of AHLE related to COVID-19 have been recorded so far [61–66]. The neurological symptoms of COVID-19 are thought to be secondary to direct viral cytotoxic effects on neurons, immune inflammation, and the development of intracranial cytokine storms [64, 67]. Recent studies show that AHLE patients have significantly higher cytokine levels than ADEM patients or noninflammatory neurological conditions [67]. SARS-CoV-2 can cause direct endothelial damage and/or secondary inflammation, as evidenced by vasculitis-like symptoms in some patients [68]. Demyelination, fibrinoid necrosis, perivascular inflammatory infiltrates, necrotizing vasculitis, and hemorrhages are all pathological features of AHLE [50]. Confined neuropathological data in COVID-19 patients show similar features in the absence of demonstrable infectious pathogens, suggesting a quasi-infectious causative mechanism [69, 70].

AHLE is characterized by undefined multifocal lesions of variable size (generally larger than 1 cm) of white matter, including the cerebral hemisphere, mainly the occipital and parietal lobes. There is a predominance of subcortical and deep white matter, with a distinctive asymmetric distribution. Although less common, brainstem, deep grey matter, and cerebellar peduncle involvement can occur [62, 71]. FLAIR and T2W images show hyperintense lesions, T1W images show hypointense lesions, and susceptibility-weighted images (SWI) show microhemorrhage-related blooming. Diffusion and contrast characteristics vary. Widespread microhemorrhages and extensive brainstem involvement are often indicators of a poor prognosis [72–74]. The presence of unifocal pseudotumoral lesions including the brainstem and corpus callosum is unusual [64, 75, 76].

Leukoencephalopathy and microhemorrhages-related changes, on the other hand, are common in critically ill COVID-19 patients with or without AHLE or ADEM clinical features. Hypoxia, sepsis, direct infection, metabolic causes, and PRES are all suspected causal factors in these patients [77]. However, imaging features favoring the presence of white matter changes with gross hemorrhage or florid micro causing a mass effect is an indication of AHLE [5].

To conclude, a COVID-19 patient with rapid neurological deterioration should prompt the treating physician to suspect AHLE, perform neuroimaging to confirm a compatible lesion pattern, and treat aggressively. Several discrepancies between ADEM and AHLE after COVID-19 infection and ADEM and AHLE without a history of prior COVID-19 infection were identified by Manzano et al. in 2021. According to Manzano et al., the great majority of recorded cases involve adults rather than children. The previous systemic infection was usually severe rather than trivial. On
neuroimaging, hemorrhagic changes within demyelinating lesions were prevalent. Despite appropriate immunotherapy, the outcome was poor [78].

High-dose IV steroids, typically methylprednisolone, remain the first-line treatment [5]. Plasma exchange and intravenous immunoglobulin (IVIG) can be used to treat refractory cases. According to a recent research of cytokines in COVID-19, tocilizumab and broad-spectrum immunomodulators are recommended for the first suspicion of AHLE [19, 67]. The treatment of COVID-19-related AHLE is still a new area and cannot be improved without more experience and knowledge of the disease.

10. Prognosis and Complications

The prognosis for AHLE is poor, with death usually occurring within a week of onset due to increased intracranial pressure (ICP) control. Psychiatric symptoms, mental deterioration, and seizures are common in survivors. Only a few patients have fully recovered [18, 33].

11. Conclusion

AHLE is a rare and rapidly fatal disease with an unknown etiology. There is a scarcity of literature on the management and presentation of this rare disease. Diagnosis is difficult because the level of evidence regarding the diagnostic yield of neuroimaging, clinical, and laboratory characteristics is still very low. Future research should concentrate on treatment characteristics and their impact on the course and outcome.

Data Availability

The data presented in this study are available within the article.

Conflicts of Interest

The author declares no conflict of interest.

Acknowledgments

The researcher would like to thank the Deanship of Scientific Research, Qassim University, for funding the publication of this project.

References

[1] L. Broderick, C. Gandhi, J. Mueller et al., “Successful treatment of acute hemorrhagic leukoencephalitis, a novel phenotype for complement factor I deficiency,” Journal of Allergy and Clinical Immunology, vol. 127, no. 2, p. A887, 2011.
[2] P. Song, W. Li, J. Xie, Y. Hou, and C. You, “Cytokine storm induced by SARS-CoV-2,” Clinica Chimica Acta, vol. 509, pp. 280–287, 2020.
[3] M. Wolska-Krawczyk, “Acute disseminated encephalomyelitis,” Der Radiologe, vol. 62, no. 4, pp. 316–321, 2022.
[4] T. Bonduelle, J. Stricker, J.-F. Minéo et al., “Weston-Hurst syndrome with acute hemorrhagic cerebellitis,” Clinical Neurology and Neurosurgery, vol. 173, pp. 118-119, 2018.
[5] P. Grzonka, M. C. Scholz, G. M. De Marchis et al., “Acute hemorrhagic leukoencephalitis: a case and systematic review of the literature,” Frontiers in Neurology, vol. 11, 2020.
[6] E. W. Hurst, “Acute haemorrhagic leukoencephalitis: a previously undefined entity,” Medical Journal of Australia, vol. 2, no. 1, pp. 1–6, 1941.
[7] E. T. Payne, J. T. Rutka, T. K. Ho, W. C. Halliday, and B. L. Banwell, “Treatment leading to dramatic recovery in acute hemorrhagic leukoencephalitis,” Journal of Child Neurology, vol. 22, no. 1, pp. 109–113, 2007.
[8] N. Duggal, I. Ahmed, and N. Duggal, “Acute hemorrhagic leukoencephalitis associated with autoimmune myopathy,” Journal of Vascular and Interventional Neurology, vol. 7, no. 4, p. 19, 2014.
[9] Y. Geerts, I. Dehaene, and M. Lammens, “Acute hemorrhagic leukoencephalitis,” Acta neurologica belgica, vol. 91, no. 4, pp. 201–211, 1991.
[10] T. A. Hardy, S. W. Reddel, M. H. Barnett, J. Palace, C. F. Lucchinetti, and B. G. Weinshenker, “Atypical inflammatory demyelinating syndromes of the CNS,” The Lancet Neurology, vol. 15, no. 9, pp. 967–981, 2016.
[11] S. Levine and E. J. Wenk, “Allergic encephalomyelitis: a hyperacute form,” Science, vol. 146, no. 3652, pp. 1681-1682, 1964.
[12] G. F. Wang, W. Li, and K. Li, “Acute encephalopathy and encephalitis caused by influenza virus infection,” Current Opinion in Neurology, vol. 23, no. 3, pp. 305–311, 2010.
[13] R. R. Singh, S. Sedani, M. Lim, E. Wassmer, and M. Absoud, “RANBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype,” European Journal of Paediatric Neurology, vol. 19, no. 2, pp. 106–113, 2015.
[14] K. Keohane and F. Gray, Infections of the Central Nervous System: Pathology and Genetics, John Wiley & Sons, 2020.
[15] L. Pagano, L. M. Larocca, M. L. Vaccario et al., “Acute hemorrhagic leukoencephalitis in patients with acute myeloid leukemia in hematologic complete remission,” Haematologica, vol. 84, no. 3, pp. 270–274, 1999.
[16] P. S. Pinto, R. Taipa, B. Moreira, C. Correia, and M. Melo-Pires, “Acute hemorrhagic leukoencephalitis with severe brainstem and spinal cord involvement: MRI features with neuropathological confirmation,” Journal of Magnetic Resonance Imaging, vol. 33, no. 4, pp. 957–961, 2011.
[17] A. T. Reder, Acute Necrotizing Hemorrhagic Leukoencephalitis, MedLink Neurology, 2006.
[18] J. A. Leake, G. F. Millman, M. P. Nespeca et al., “Pediatric acute hemorrhagic leukoencephalitis: report of a surviving patient and review,” Clinical Infectious Diseases, vol. 34, no. 5, pp. 699–703, 2002.
[19] B. Varadan, A. Shankar, A. Rajakumar et al., “Acute hemorrhagic leukoencephalitis in a COVID-19 patient—a case report with literature review,” Neuroradiology, vol. 63, no. 5, pp. 653–661, 2021.
[20] E. H. Kolodny, “Dysmyelinating and demyelinating conditions in infancy,” Current Opinion in Neurology and Neurosurgery, vol. 6, no. 3, pp. 379–386, 1993.
[21] H. Y. Lim, V. P. Y. Ho, T. C. C. Lim, T. Thomas, and D. W. S. Chan, “Serial outcomes in acute necrotising encephalopathy of
childhood: a medium and long term study,” Brain and Development, vol. 38, no. 10, pp. 928–936, 2016.

[22] R. Sonnevile, I. F. Klein, and M. Wolff, “Update on investigation and management of postinfectious encephalitis,” Current Opinion in Neurology, vol. 23, no. 3, pp. 300–304, 2010.

[23] M. A. Lann, M. A. Lovell, and B. K. Kleinshmidt-DeMasters, “Acute hemorrhagic leukoencephalitis,” The American Journal of Forensic Medicine and Pathology, vol. 31, no. 1, pp. 7–11, 2010.

[24] A. Panchal and F. Perez-Marques, “Intravenous immunoglobulin for acute hemorrhagic leukoencephalitis refractory to plasmapheresis,” Clinical Case Reports, vol. 7, no. 1, pp. 160–163, 2019.

[25] D. Karussis, “The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review,” Journal of Autoimmunity, vol. 48-49, pp. 134–142, 2014.

[26] W. N. Gibbs, M. A. Kreidie, R. C. Kim, and A. N. Hasso, “Acute hemorrhagic leukoencephalitis,” Journal of Computer Assisted Tomography, vol. 29, no. 5, pp. 689–693, 2005.

[27] I. Pirko, G. L. Suidan, M. Rodriguez, and A. J. Johnson, “Acute hemorrhagic demyelination in a murine model of multiple sclerosis,” Journal of Neuroinflammation, vol. 5, no. 1, pp. 1–5, 2008.

[28] Ö. Yildiz, R. Pul, P. Raab, C. Hartmann, T. Skripuletz, and W. G. Solis, S. E. Waller, A. K. Harris, E. Sugo, M. A. Hansen, and J. Lechner-Scott, “Favourable outcome in a 33-year-old female with acute haemorrhagic leukoencephalitis,” Case Reports in Neurology, vol. 9, no. 1, pp. 106–113, 2017.

[29] S. Tenembaum, T. Chitnis, J. Ness, J. S. Hahn, and for the International Pediatric MS Study Group, “Acute disseminated encephalomyelitis,” Neurology, vol. 68, 16, Supplement 2, pp. S23–S36, 2007.

[30] D. S. Khurana, J. J. Melvin, S. V. Kotheare et al., “Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis,” Pediatrics, vol. 116, no. 2, pp. 431–436, 2005.

[31] N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China, 2019,” New England Journal of Medicine, vol. 382, no. 8, pp. 727–733, 2020.

[32] J. J. Lou, M. Movassagh, D. Gordy et al., “Neuropathology of COVID-19 (neuro-COVID): clinicopathological update,” Free neuropathology, vol. 2, 2021.

[33] J. R. Lechien, C. M. Chiesa-Estomba, D. R. De Siati et al., “Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study,” European Archives of Oto-Rhino-Laryngology, vol. 277, no. 8, pp. 2251–2261, 2020.

[34] L. Fodoulian, J. Tuberosa, D. Rossier et al., “SARS-CoV-2 receptors and entry genes are expressed in the human olfactory neuroepithelium and brain,” iScience, vol. 23, no. 12, article 101839, 2020.

[35] F. Salamanna, M. Maglio, M. P. Landini, and M. Fini, “Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2,” Frontiers in Medicine, vol. 7, p. 935, 2020.

[36] D. H. Brann, T. Tsukahara, C. Weinreb et al., “Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia,” Science Advances, vol. 6, no. 31, article eabc5801, 2020.

[37] H. Xia and E. Lazartigues, “Angiotensin-converting enzyme 2 in the brain: properties and future directions,” Journal of Neurochemistry, vol. 107, no. 6, pp. 1482–1494, 2008.

[38] M. Gheblawi, K. Wang, A. Viveiros et al., “Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2,” Circulation Research, vol. 126, no. 10, pp. 1456–1474, 2020.

[39] J. Meinhardt, J. Radke, C. Dittmayer et al., “Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19,” Nature Neuroscience, vol. 24, no. 2, pp. 168–175, 2021.

[40] J. Matschke, M. Lütgehetmann, C. Hagel et al., “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series,” The Lancet Neurology, vol. 19, no. 11, pp. 919–929, 2020.

[41] C. H. von Weyhern, I. Kaufmann, F. Neff, and M. Kremer, “Early evidence of pronounced brain involvement in fatal COVID-19 outcomes,” The Lancet, vol. 395, no. 10241, article e109, 2020.

[42] G. Goshua, A. B. Pine, M. L. Meizlish et al., “Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study,” The Lancet Haematology, vol. 7, no. 8, e575–e582, 2020.

[43] V. P. Fabbri, M. P. Foschini, T. Lazzarotto et al., “Brain ischaemic injury in COVID-19-infected patients: a series of 10 post-mortem cases,” Brain Pathology, vol. 31, no. 1, pp. 205–210, 2021.

[44] F. Hernández-Fernández, H. Sandoval Valencia, R. A. Barbella-Aponte et al., “Cerebrovascular disease in patients with
COVID-19: neuroimaging, histological and clinical description,” *Brain*, vol. 143, no. 10, pp. 3089–3103, 2020.

[54] T. Parsons, S. Banks, C. Bae, J. Gelber, H. Alahmadi, and M. Tichauer, “COVID-19-associated acute disseminated encephalomyelitis (ADEM),” *Journal of Neurology*, vol. 267, no. 10, pp. 2799–2802, 2020.

[55] G. Novi, T. Rossi, E. Pedemonte et al., “Acute disseminated encephalomyelitis after SARS-CoV-2 infection,” *Neurology Neuroimmunology Neuroinflammation*, vol. 7, no. 5, article e799, 2020.

[56] S. Abdi, A. Ghorbani, and F. Fatehi, “The association of SARS-CoV-2 infection and acute disseminated encephalomyelitis without prominent clinical pulmonary symptoms,” *Journal of the Neurological Sciences*, vol. 416, p. 117001, 2020.

[57] V. Sawlani, S. Scotton, K. Nader et al., “COVID-19-related intracranial imaging findings: a large single-centre experience,” *Clinical Radiology*, vol. 76, no. 2, pp. 108–116, 2021.

[58] R. R. Reichard, K. B. Kashani, N. A. Boire, E. Constantopoulos, Y. Guo, and C. F. Lucchinetti, “Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology,” *Acta Neuropathologica*, vol. 140, no. 1, pp. 1–6, 2020.

[59] J. M. Walker, A. R. Gilbert, K. F. Bieniek, and T. E. Richardson, “COVID-19 patients with CNS complications and neuropathologic features of acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalopathy,” *Journal of Neuropathology & Experimental Neurology*, vol. 80, no. 6, pp. 628–631, 2021.

[60] C. Bryce, Z. Grimes, E. Pujadas et al., “Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience,” *Modern Pathology*, vol. 34, no. 8, pp. 1456–1467, 2021.

[61] A. Challi, C. S. Baker, R. B. Johnston et al., “Acute Hemorrhagic Encephalitis Related to COVID-19,” vol. 11, no. 2, 2021, Clinical Practice, *Neurology*, 2021.

[62] R. Handa, S. Nanda, A. Prasad et al., “Covid-19-associated acute haemorrhagic leukoencephalomyelitis,” *Neurological Sciences*, vol. 41, no. 11, pp. 3023–3026, 2020.

[63] T. Karapanayiotides, E. Geka, P. Prassopoulos et al., “Cencent demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?” *Brain*, vol. 143, no. 12, pp. e100–e100, 2020.

[64] P. Perrin, N. Collongues, S. Baloglu et al., “Cytokine release syndrome-associated encephalopathy in patients with COVID-19,” *European Journal of Neurology*, vol. 28, no. 1, pp. 248–258, 2021.

[65] R. Ghosh, S. Dubey, J. Finsterer, S. Chatterjee, and B. K. Ray, “SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report,” *The American journal of case reports*, vol. 21, pp. e925641–e925641, 2020.

[66] A. Haqiqi, T. L. Samuels, F. J. Lamb, T. Moharrum, and A. E. Myers, “Acute haemorrhagic leukoencephalitis (Hurst disease) in severe COVID-19 infection,” *Brain, Behavior, & Immunity-Health*, vol. 12, article 100208, 2021.

[67] M. Waak, S. Malone, K. Sinclair et al., “Acute hemorrhagic leukoencephalopathy: pathological features and cerebrospinal fluid cytokine profiles,” *Pediatric Neurology*, vol. 100, pp. 92–96, 2019.

[68] R. Hanafi, P.-A. Roger, B. Perin et al., “COVID-19 neurologic complication with CNS vasculitis-like pattern,” *American Journal of Neuroradiology*, vol. 41, no. 8, pp. 1384–1387, 2020.

[69] M. Salgarelli, G. Visconti, and L. Barone-Adesi, “Interlocking circumareolar suture with undyed polyamide thread: a personal experience,” *Aesthetic Plastic Surgery*, vol. 37, no. 5, pp. 1061-1062, 2013.

[70] S. Al-Sarraj, C. Troakes, B. Hanley et al., “Invited review: the spectrum of neuropathology in COVID-19,” *Neuropathology and Applied Neurobiology*, vol. 47, no. 1, pp. 3–16, 2021.

[71] M. H. Yong, Y. F. Z. Chan, J. Liu et al., “A rare case of acute hemorrhagic leukoencephalitis in a COVID-19 patient,” *Journal of the Neurological Sciences*, vol. 416, p. 117035, 2020.

[72] S. Agarwal, R. Jain, S. Dogra et al., “Cerebral microbleeds and leukoencephalopathy in critically ill patients with COVID-19,” *Stroke*, vol. 51, no. 9, pp. 2649–2655, 2020.

[73] L. Dixon, J. Varley, A. Gontsarova et al., “COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia,” *Neurology Neuroimmunology Neuroinflammation*, vol. 7, no. 5, p. e789, 2020.

[74] R. W. Paterson, R. L. Brown, L. Benjamin et al., “The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings,” *Brain*, vol. 143, no. 10, pp. 3104–3120, 2020.

[75] R. D. Arenas and E. S. Hernandez, “Pseudotumoral lesion as a manifestation of acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome),” *Multiple Sclerosis and Related Disorders*, vol. 46, article 102583, 2020.

[76] N. E. Abou Zeid, J. D. Burns, E. F. Wijdicks, C. Giannini, and B. M. Keegan, “Atypical acute hemorrhagic leukoencephalitis (Hurst’s disease) presenting with focal hemorrhagic brainstem lesion,” *Neurocritical Care*, vol. 12, no. 1, pp. 95–97, 2010.

[77] A. Radmanesh, A. Derman, Y. W. Lui et al., “COVID-19–associated diffuse leukoencephalopathy and microhemorrhages,” *Radiology*, vol. 297, no. 1, pp. E223–E227, 2020.

[78] G. S. Manzano, C. R. McEntire, M. Martinez-Lage, F. J. Mateen, and S. K. Hutto, “Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis,” *Neurology Neuroimmunology Neuroinflammation*, vol. 8, no. 6, 2021.